{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:11:47Z","timestamp":1722323507735},"reference-count":31,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2017.7271","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T08:36:48Z","timestamp":1509007008000},"source":"Crossref","is-referenced-by-count":3,"title":["A retrospective comparison of Escherichia\u00ef\u00bf\u00bdcoli and polyethylene glycol\u2011conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia"],"prefix":"10.3892","author":[{"given":"Jiabao","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xutao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"key20200714081657_b1-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.clml.2014.06.017","article-title":"Asparaginase in Acute Lymphoblastic Leukemia","volume":"14","author":"Kawedia","year":"2014","journal-title":"Clin Lymph Myelom Leukem"},{"key":"key20200714081657_b2-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2015.01.002","article-title":"Recent developments in L-asparaginase discovery and its potential as anticancer agent","volume":"100","author":"Shrivastava","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20200714081657_b3-ol-0-0-7271","first-page":"31","article-title":"Acute lymphocytic leukemia in adults. Pathologic features and prognosis","volume":"53","author":"Marinescu","year":"2015","journal-title":"Rom J Intern Med"},{"key":"key20200714081657_b4-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"key20200714081657_b5-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"key20200714081657_b6-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91\u201301","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"key20200714081657_b7-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95\u201301 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"key20200714081657_b8-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20200714081657_b9-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"key20200714081657_b10-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/MPH.0b013e3180640d54","article-title":"Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: A report from the Children's Oncology Group","volume":"29","author":"Salzer","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20200714081657_b11-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"key20200714081657_b12-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.addr.2012.10.014","article-title":"Polymer-drug conjugates: Origins, progress to date and future directions","volume":"65","author":"Kope\u010dek","year":"2013","journal-title":"Adv Drug Deliver Rev"},{"key":"key20200714081657_b13-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.addr.2007.04.018","article-title":"Anti-cancer PEG-enzymes: 30 years old, but still a current approach","volume":"60","author":"Pasut","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"key20200714081657_b14-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"key20200714081657_b15-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00043426-200203000-00004","article-title":"A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: The Children's Cancer Group study (CCG-1962)","volume":"24","author":"Kurre","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20200714081657_b16-ol-0-0-7271","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)[S\/OL]Acute Lymphoblastic Leukemia. Version 12015http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"key20200714081657_b17-ol-0-0-7271","unstructured":"National Cancer Institute [S\/OL]Common Terminology Criteria for Adverse Events (CTCAE) Mar 42010http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5\u00d77.pdf"},{"key":"key20200714081657_b18-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00\u201301","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200714081657_b19-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20200714081657_b20-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1517\/14712591003769808","article-title":"Peg-asparaginase for acute lymphoblastic leukemia","volume":"10","author":"Rytting","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"key20200714081657_b21-ol-0-0-7271","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1684\/bdc.2010.1168","article-title":"Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia","volume":"97","author":"Thomas","year":"2010","journal-title":"Bull Cancer"},{"key":"key20200714081657_b22-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: A review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"key20200714081657_b23-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"key20200714081657_b24-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/clpt.2009.162","article-title":"Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia","volume":"86","author":"Panetta","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key20200714081657_b25-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2010.10.019","article-title":"Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881","volume":"47","author":"Sirvent","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20200714081657_b26-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"key20200714081657_b27-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bjh.12865","article-title":"Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia","volume":"166","author":"Henriksen","year":"2014","journal-title":"Br J Haematol"},{"key":"key20200714081657_b28-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia","volume":"119","author":"Kawedia","year":"2012","journal-title":"Blood"},{"key":"key20200714081657_b29-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/pbc.24182","article-title":"Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia","volume":"59","author":"Merryman","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"key20200714081657_b30-ol-0-0-7271","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"Avramis","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"key20200714081657_b31-ol-0-0-7271","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T14:15:58Z","timestamp":1603203358000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.7271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":31,"URL":"https:\/\/doi.org\/10.3892\/ol.2017.7271","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}